Leukemia: Clinical Trials

16 trials for Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 suspended. 16 Phase 2, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 216Suspended 16
Phase 16Suspended 6

Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pyronaridine in Acute Myeloid Leukemia (AML)
Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2SuspendedArmaceutica, Inc.2002028-02-212026-10-19
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Phase 2SuspendedUniversity of Washington302026-05-082026-09-29
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia
Phase 2SuspendedLeland Metheny202026-04-082026-09-10
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Eltrombopag (EPAG) - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Phase 2SuspendedAbhay Singh, MD MPH252025-06-172026-10-09
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL
Phase 1 / Phase 2SuspendedSymBio Pharmaceuticals432025-06-092026-02-05
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Dasatinib - Acute Myeloid Leukemia
Phase 2SuspendedInstitut Paoli-Calmettes352024-05-222026-10-01
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
fadraciclib - Leukemia, Myelodysplastic Syndrome(MDS)
Phase 1 / Phase 2SuspendedCyclacel Pharmaceuticals, Inc.2102021-10-222024-02-08
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
IBI188, Azacitidine, Decitabine - Acute Myeloid Leukemia
Phase 1 / Phase 2SuspendedInnovent Biologics (Suzhou) Co. Ltd.2222020-09-252023-10-23
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Emavusertib, Venetoclax - Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Phase 1 / Phase 2SuspendedCuris, Inc.3662020-07-062026-03-19
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
Oshadi D & Oshadi R;, salvage therapy cytosar and mitoxantrone - Acute Myeloid Leukemia, Lymphoid Leukemia
Phase 2SuspendedOshadi Drug Administration152017-01-012018-04-18
CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation
CLAM+PBSC - Leukemia
Phase 1 / Phase 2SuspendedShanghai Jiao Tong University School of Medicine202016-09-012021-11-26
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients
AS101 - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 2SuspendedBioMAS Ltd122015-01-012015-02-10
Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
Alemtuzumab - B-cell Chronic Lymphocytic Leukemia
Phase 2SuspendedShanghai Zhangjiang Biotechnology Limited Company1202011-07-012022-06-21
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
KB004, Monoclonal Antibody - Myelodysplastic Syndrome (MDS), Myelofibrosis (MF)
Phase 1 / Phase 2SuspendedHumanigen, Inc.1202010-09-012015-11-17
L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes
L-Ascorbic Acid - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 2SuspendedSamsung Medical Center251998-05-012006-10-26
Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
Imatinib Mesylate - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
Phase 2SuspendedRenato Melaragno202013-03-26

Narrower conditions

Leukemia, Myeloid, Acute (8)  ·  Myelodysplastic Syndromes (7)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Leukemia, Myelomonocytic, Chronic (2)  ·  Lymphoma (2)  ·  Neoplasms (2)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Recurrence (2)  ·  Burkitt Lymphoma (1)  ·  Epstein-Barr Virus Infections (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Hodgkin Disease (1)  ·  Immunoblastic Lymphadenopathy (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)

Broader conditions

Hematologic Diseases (16)  ·  Hemic and Lymphatic Diseases (16)  ·  Neoplasms by Histologic Type (16)  ·  Neoplasms (14)  ·  Leukemia, Myeloid (9)  ·  Bone Marrow Diseases (7)  ·  Immune System Diseases (7)  ·  Immunoproliferative Disorders (7)  ·  Lymphatic Diseases (7)  ·  Lymphoproliferative Disorders (7)  ·  Leukemia, Lymphoid (6)  ·  Disease Attributes (5)  ·  Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)

Interventions

Cyclophosphamide (2)  ·  Abatacept (1)  ·  Alemtuzumab (1)  ·  Antineoplastic Agents (1)  ·  Ascorbic Acid (1)  ·  Asparaginase (1)  ·  Azacitidine (1)  ·  CA-4948 (1)  ·  CT-P10 (1)  ·  CYC065 (1)  ·  Dasatinib (1)  ·  Decitabine (1)  ·  Doxorubicin (1)  ·  Etoposide (1)  ·  Filgrastim (1)

Sponsors

Abhay Singh, MD MPH (1)  ·  Armaceutica, Inc. (1)  ·  BioMAS Ltd (1)  ·  Curis, Inc. (1)  ·  Cyclacel Pharmaceuticals, Inc. (1)  ·  Humanigen, Inc. (1)  ·  Innovent Biologics (Suzhou) Co. Ltd. (1)  ·  Institut Paoli-Calmettes (1)  ·  Leland Metheny (1)  ·  Oshadi Drug Administration (1)  ·  Renato Melaragno (1)  ·  Samsung Medical Center (1)  ·  Shanghai Jiao Tong University School of Medicine (1)  ·  Shanghai Zhangjiang Biotechnology Limited Company (1)  ·  SymBio Pharmaceuticals (1)

Countries

United States (6)  ·  China (4)  ·  France (2)  ·  Israel (2)  ·  Australia (1)  ·  Czechia (1)  ·  Germany (1)  ·  Italy (1)  ·  Japan (1)  ·  Poland (1)  ·  Senegal (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Abhay Singh, MD, MPH (1)  ·  Jiong HU, M.D., (1)  ·  Jun Zhu, M.D. (1)  ·  Leland Metheny, MD (1)  ·  Morgan Lam (1)  ·  Moshe Gatt, MD (1)  ·  Renato J Aguilera, PhD (1)  ·  Ryan D. Cassaday, MD (1)  ·  Won Seog Kim, MD (1)

Results publications

PMID 19284416, PMID 27736729